What the National Cancer Institute, NCI Is Studying About Ivermectin in 2026?

Ivermectin June 5, 2026

The cancer is accounted for millions of death globally every year in USA, UK, Australia and other parts of the world. People are questioning about the viability of Ivermectin for tumor treatment. If you have spent your precious time on internet, joining and reading on the cancer communities or taken interest in the livestock medicines, if the period of last 50 years, you probably come across antiparasitic medicines like Ivermectin, fenbendazole.

How deworming pills- Ivermectin, Fenbendazole become repurposed therapy for tumor?

The deworming formulations since ages has been utilised for taking care of the parasitic infections in humans and animals like river blindness, scabies – and is the common fixture.
But from the last few years, there has been so much abuzz about ivermectin as potential tumor treatment. and this year in 2026, the conversation got even louder when esteemed National Cancer Institute, NCI has made confirmation, that it is actively conducting preclinical research on studying the anti tumor characteristics of ivermectin.

In this blog post, let’s explore reasons why Ivermectin, Fenbendazole 222 mg are back in conversation, what national Cancer Institute, NCI, USA is actually studying, and can oncologist recommend this repurposed medicine for tumor treatment in future? Continue reading the content to know more about the NCI funding to the tumor innovation fund targeting the research on repurposed drug like ivermectin

What is ivermectin? Its uses, historical significance, FDA approval

The Ivermectin is age old anti parasitic medicine, effectively utilised for curing animals and human beings.
In the decade of 1980s, this deworming pill became the best-selling formulation, because of the potency of treating ectoparasite and endoparasite infections.
And later it has got approval FDA, USA, for the treatment against the roundworm infection and treating river blindness.
The combination of these antiparasitic medicines Ivermectin 12 mg, Fenbendazole, approved by FDA has found to decrease the proliferation of the tumor cell. They work by cutting of the blood supply to the tumor cells, triggering the termination.
There are 84% of the patients that have reported to be benefited from Ivermectin dosage and protocol from the tumors of prostate, breast, lung, ovary, lymphoma and other organs of the body.

Reasons why National Cancer Institute to the step to study ivermectin for cancer treatment

In early months of this year, NCI officials have come up for the preclinical research for investigating the potential of this antiparasitic medicine for tumor cure.

Some of the reasons why this National level agency is studying the repurposed, alternative medicine:

There has been increasing interest of the public at large in this alternative tumor therapy
Also due to the increase discussion in podcast and social media channels about the viability of Ivermectin for cancer
The early laboratory researchers have suggested, that this deworming pill is capable of triggering apoptosis tumor cellular mortality, effective metabolism, impact of metabolic Pathways and can even interfere with the tumor cellular signalling.
Ivermectin and immunotherapy medications are being tested in one ongoing early-phase clinical trial (Phase 1/2, NCT05318469) at Cedars-Sinai Medical Center for metastatic triple-negative breast cancer. Six of the eight patients that could be evaluated had progressing illness.
Because ivermectin was used in conjunction with approved immunotherapy medications, it is challenging to ascertain whether any effect was attributable to ivermectin alone or to the immunotherapy medications.
However, two individuals did exhibit some benefit. Full results are expected by late 2026, and even if promising, a much larger Phase 3 trial would still be needed before this could become a standard treatment.